One Year into Filosa, Stellantis Turnaround Still Unproven

What happened

One year into CEO Antonio Filosa's tenure at Stellantis, investor sentiment remains harsh as operational results are mixed and key strategic initiatives are still in early stages. The stock trades at just 2.9x earnings, reflecting deep skepticism about the company's ability to navigate European overcapacity and North American profit erosion. While the $13B U.S. reinvestment and multi-energy pivot offer a potential recovery, industrial free cash flow turned sharply negative in 2024 and Italian output hit a 68-year low in 2025. The CEO transition and interim governance add uncertainty, and the market is waiting for H2 2025 results and the 2026 Capital Markets Day to confirm whether the turnaround is on track. For now, the valuation discounts a lot of bad news, but evidence of sustained recovery remains elusive, keeping the stock in a wait-and-see territory.

Implication

The one-year CEO report card confirms that Stellantis's turnaround is still unproven, making the stock a speculative bet on execution rather than a value play. Near-term catalysts include H2 2025 results and the 2026 Capital Markets Day, which must show tangible improvement in North America margins and European utilization. The low valuation (P/E ~2.9x) provides a margin of safety on solvency, but earnings durability is weak, so position sizing must account for high volatility. If the recovery falters, the stock could remain a value trap, especially with negative industrial FCF and heavy capex commitments. Patience is warranted; the attractive entry is near $9.00, with trim above $14.50.

Thesis delta

The one-year performance under CEO Filosa has not altered the fundamental thesis that Stellantis's turnaround hinges on successful execution of its U.S. reinvestment and European restructuring. However, the harsh investor verdict and mixed operational data underscore that the path to recovery is narrower and slower than initially hoped. This reinforces our WAIT rating and the need for more evidence before upgrading to a buy.